Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Bioconjug Chem. 2008 Jul 12;19(8):1579–1587. doi: 10.1021/bc800110y

Figure 4.

Figure 4

Targeting of HER2-expressing xenografts in vivo. Left panel: Biodistribution of 111In-CHX-A” DTPA-Z2395-C 1, 4 and 24 h pi. Right panel: Specificity of 111In-CHX-A” DTPA-Z2395-C tumor uptake in SKOV-3 xenografts, 4 h p.i. In order to saturate HER2 receptors in tumors, one group of animals was preinjected with 520 μg nonlabeled ZHER2:342 45 min before injection of radiolabeled conjugate (designated as blocking). All animals were injected with 1 μg of labeled Affibody molecules.

Data are expressed as % IA/g (percent of injected radioactivity per gram tissue) and presented as an average from four animals ± SD.

*Data for the gastrointestinal tract (with its content) and for carcass are presented as % IA per whole sample.